DEVELOPING A NOVEL UMBILICAL CORD BLOOD-DERIVED CELL THERAPY TO SUPPRESS NEUROINFLAMMATION AND PROMOTE REMYELINATION

$1,000,000FY2025Defense Health AgencyDOD

Duke University, Durham NC

Investigators